Olympus launches POWERSEAL Sealer/Divider, a next level surgical bipolar energy device in EMEA Olympus has announced the full market launch of POWERSEAL Sealer/Divider for the Europe, Middle East and Africa (EMEA) region. This...
Journal watch 24/05/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
B cells promote liver cancer with dangerous dual strategyAn increase in the numbers of activated B cells in the gastrointestinal tract drive inflammatory fatty liver disease (NASH, non-alcoholic...
Endotoxin fragments help drive obesityNottingham Trent University researchers have found that microbe fragments called endotoxin enter the blood stream and directly impact how...
OASIS 1 trial: Oral semaglutide 50mg achieves 15.1% weight lossHeadline results from OASIS 1 - a phase 3a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight...
ABarginase shows promising outcomes for treating multiple obesity-related metabolic diseasesResearchers from The Hong Kong Polytechnic University (PolyU) and The Chinese University of Hong Kong (CUHK) have reported a...
Semaglutide decreases cardiovascular risk score after one year of useTwo new studies presented at this year's European Congress on Obesity have revealed that semaglutide is effective for weight loss in a...